Bullfrog AI (NASDAQ:BFRG) & Rapid Micro Biosystems (NASDAQ:RPID) Head-To-Head Survey

Rapid Micro Biosystems (NASDAQ:RPID) and Bullfrog AI (NASDAQ:BFRG) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Institutional and Insider Ownership

52.6% of Rapid Micro Biosystems shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 12.7% of Rapid Micro Biosystems shares are owned by insiders. Comparatively, 14.7% of Bullfrog AI shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Rapid Micro Biosystems and Bullfrog AI”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapid Micro Biosystems	$33.59 million	1.67	-$47.12 million	($1.12)	-1.00
Bullfrog AI	$120,000.00	71.66	-$6.50 million	($0.46)	-1.01

Bullfrog AI has lower revenue, but higher earnings than Rapid Micro Biosystems. Bullfrog AI is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Rapid Micro Biosystems and Bullfrog AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%
Bullfrog AI	N/A	-150.36%	-127.98%

Analyst Ratings

This is a summary of current ratings and price targets for Rapid Micro Biosystems and Bullfrog AI, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapid Micro Biosystems	1	0	2	0	2.33
Bullfrog AI	1	1	0	0	1.50

Rapid Micro Biosystems currently has a consensus target price of $6.00, suggesting a potential upside of 435.71%. Given Rapid Micro Biosystems’ stronger consensus rating and higher probable upside, analysts clearly believe Rapid Micro Biosystems is more favorable than Bullfrog AI.

Risk & Volatility

Rapid Micro Biosystems has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of -2.71, meaning that its stock price is 371% less volatile than the S&P 500.

Summary

Rapid Micro Biosystems beats Bullfrog AI on 8 of the 14 factors compared between the two stocks.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.